Clinical trial
Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to 5-Fluorouracil…
NCT00131599 · AHS Cancer Control Alberta, Other · Unknown status
Key facts
| NCT number | NCT00131599 |
|---|---|
| Title | Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to 5-Fluorouracil Based Chemotherapy in Stage III Colon Cancer |
| Official title | Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to 5-Fluorouracil Based Chemotherapy in Stage III Colon Cancer |
| Lead sponsor | AHS Cancer Control Alberta, Other |
| Status | Unknown status |
| Study type | Observational |
| Conditions | Colon Cancer |
| Intervention type | Drug |
| Interventions | 5FU/LV |
| Enrollment | 104 |
| Start date | Aug 1, 2002 |
| Primary completion | Jul 1, 2017 |
| Completion | Jul 1, 2017 |
| First posted | Aug 19, 2005 |
| Last update posted | Jan 16, 2017 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: